D.E. Shaw & Co’s ResMed RMD Stock Holding History

D.E. Shaw & Co’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,000	Closed	-$2.29M	–	4666
2024 Q4	$2.29M	Buy	+10,000	New	+$2.41M	﹤0.01%	2625
2022 Q4	–	Sell	-24,500	Closed	-$5.35M	–	5081
2022 Q3	$5.35M	Hold	24,500	–	–	0.01%	2013
2022 Q2	$5.14M	Hold	24,500	–	–	0.01%	2091
2022 Q1	$5.94M	Sell	24,500 -6,800	-22%	-$1.64M	0.01%	2121
2021 Q4	$8.15M	Hold	31,300	–	–	0.01%	1872
2021 Q3	$8.25M	Buy	+31,300	New	+$8.56M	0.01%	1663
2020 Q3	–	Sell	-44,800	Closed	-$8.6M	–	4105
2020 Q2	$8.6M	Sell	44,800 -7,100	-14%	-$1.16M	0.01%	1282
2020 Q1	$7.64M	Buy	51,900 +20,300	+64%	+$3.23M	0.01%	1158
2019 Q4	$4.9M	Buy	31,600 +24,500	+345%	+$3.53M	0.01%	1751
2019 Q3	$959K	Buy	+7,100	New	+$930K	﹤0.01%	2855
2016 Q1	–	Sell	-20,000	Closed	-$1.07M	–	3722
2015 Q4	$1.07M	Hold	20,000	–	–	﹤0.01%	2587
2015 Q3	$1.02M	Hold	20,000	–	–	﹤0.01%	2598
2015 Q2	$1.13M	Buy	20,000 +10,000	+100%	+$631K	﹤0.01%	2615
2015 Q1	$718K	Buy	+10,000	New	+$650K	﹤0.01%	2811

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co's RMD Position: Q1 2026 in Review

D.E. Shaw & Co reduced its ResMed (RMD) stake by 51% in Q1 2026, selling an estimated $2.99M and leaving 11,576 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2712.

D.E. Shaw & Co first reported a position in RMD in Q2 2013 and has held it in 44 quarters since. The position peaked at $97.2M in Q3 2023. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

D.E. Shaw & Co held 11,576 shares of ResMed worth $2.6M as of Q1 2026.
D.E. Shaw & Co sold 12,013 ResMed shares in Q1 2026, an estimated $2.99M.
ResMed made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2712 holding.
D.E. Shaw & Co first reported a position in ResMed in Q2 2013 and has held it in 44 quarters since.
D.E. Shaw & Co's ResMed position peaked at $97.2M in Q3 2023.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.